Improvement of peripheral blood lymphocyte subsets in primary biliary cirrhosis after ursodeoxycholic acid therapy.
Immunological abnormalities frequently observed in patients with primary biliary cirrhosis are considered to be related to the pathogenesis of this disease. We performed a prospective trial to evaluate whether immune mechanisms play a role in the effectiveness of ursodeoxycholic acid (UDCA) therapy. Fifteen female patients with primary biliary cirrhosis were followed for 1 year and were then treated with UDCA (600 mg/day) for another year. Laboratory tests, including peripheral blood lymphocyte subsets assessed by dual colour fluorescence analysis using monoclonal antibodies against respective T cell markers, were evaluated at the beginning of the study, at the start of therapy and at the end of therapy. In primary biliary cirrhosis, the proportion of cytotoxic T cells, suppressor inducer T cells and alpha beta-receptor bearing T cells were significantly lower than in healthy controls. No significant changes were observed in the proportions during the year before the therapy. These reductions, however, recovered to normal ranges after 1 year of UDCA therapy. These changes were associated with an improvement in the serum levels of aspartate aminotransferase, alkaline phosphatase, gamma-globulin and IgM. The close correlation between the improvement in the imbalance of lymphocyte subsets after the therapy and the clinical status suggests that an immunological process may play a role in the effectiveness of therapy in primary biliary cirrhosis.
Ikeda
T
T
Department of Internal Medicine, Yokosuka Kyousai Hospital, Kanagawa, Japan.
Sato
C
C
Noguchi
O
O
Kobayashi
F
F
Tozuka
S
S
Sakamoto
S
S
Marumo
F
F
D000368:Aged; D001773:Blood Cells / Q000187:drug effects / Q000473:pathology*; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000097:blood* / Q000188:drug therapy*; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000473:pathology*; D008875:Middle Aged; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D014580:Ursodeoxycholic Acid